Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$8975 of $63500 - as of 2024-02-29
14%
Header Image
Centanafadine for ADHD

Sitemap

Centanafadine for ADHD

Centanafadine is a

  • Noradrenaline reuptake inhibitors
  • Dopamine reuptake inhibitors
  • Serotonin reuptake inhibitors.

Two randomized, double-blind, placebo-controlled, parallel-group, phase 3 studies were conducted in adults with ADHD using 200 mg/d or 400 mg/d centanafadine extended-release tablets.1
At day 42, both studies showed improvements in AISRS total score compared to placebo with effect sizes of -0.28 for 200 mg/d and -0.24 for 400 mg/d in study 1 and -0.37 for 200 mg/d and -0.40 for 400 mg/d in study 2.

Centanafadine was well tolerated and the overall rate of adverse events was low, but dose-dependent.

Centanafadine is currently being studied in several clinical trials for its efficacy and safety in children and adolescents with ADHD (NCT05279313, NCT05428033, NCT05257265).2